EMA accepts Iveric Bio’s avacincaptad pegol (ACP) for MAA review


The geographic atrophy treatment was approved by the FDA in the US earlier this month.

People gather around a desk as a document is stamped for approval. Image credit: ©88studio – stock.adobe.com

Pravin U. Dugel, MD, president of Iveric Bio, called the acceptance of the MAA a “key milestone” in the ongoing global fight against geographic atrophy. Image credit: ©88studio – stock.adobe.com

Iveric Bio, a subsidiary of Astellas Pharma Inc., announced an update on the European status of its avacincaptad pegol (ACP) intravitreal solution for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The European Medicines Agency (EMA) has accepted the product’s marketing authorisation application (MAA) for regulatory review.1 The announcement follows the product’s FDA approval in the US earlier this month.

In a news release, Iveric Bio described the product as an investigational complement C5 inhibitor for the treatment of GA secondary to AMD. The GATHER1 and GATHER2 Phase 3 clinical trials evaluated the safety and efficacy of monthly 2 mg intravitreal administration of ACP in patients with GA secondary to AMD. According to the company, primary analysis of each registrational trial showed a statistically significant reduction in the rate of GA growth in patients treated with ACP compared to sham.1 Over 700 patients were evaluated in the two trials over a 12-month period.

Pravin U. Dugel, MD, president of Iveric Bio, called the acceptance of the MAA a “key milestone” in the ongoing global fight against GA, a leading cause of blindness. "We look forward to collaborating with CHMP throughout the review process and hope to make ACP available for patients in Europe,” Dugel said in a statement.

In the US, ACP was approved as IZERVAY™ on 4 August, 2023. The press release noted that acceptance of the MAA is not expected to have an impact on financial forecasts of the current fiscal year.


1. European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy. News release. Astellas Pharma Inc., August 18, 2023.
Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.